Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI's Potential
Summary
After two decades running Spotify to well over 700 million active users and more than 300 million premium subscribers, Daniel Ek became executive chairman on January 1 and returned to building. Spotify began in 2006, launched in Sweden in late 2008 and reached the U.S. in 2011; Neko Health similarly spent five years developing before launching in Sweden in 2023, followed by the U.K. and now the U.S. “Maybe I just have a high pain tolerance.”
Neko’s wedge is a vertically integrated, $499 preventive-health visit with positive unit economics. In roughly an hour, it measures 53 blood markers, captures more than 6,000 high-resolution body images, evaluates cardiovascular and other established indicators, and delivers the results through a clinician. Ek calls it “the most valuable hour you can invest in your health.” Neko co-founder Hjalmar Nilsonne is the brainchild and handles most of the work; Ek is not its day-to-day CEO.
More than 100,000 scans have produced an early health signal: roughly 1% of members had a serious, previously undiagnosed condition discovered. Ek says members with the worst starting health status have improved the most, while explicitly stopping short of claiming conclusive population-level outcomes. Neko recommends annual visits, but he says it is too early to know what broad adoption would do to healthcare budgets.
Dermatology illustrates why Neko views multimodal, longitudinal data as the product rather than a one-off checkup. The average person at Neko has roughly 950 moles; Neko indexes them all, uses AI to flag risks, layers clinician and specialist review on top, then compares every lesion across visits. Even an exceptional doctor “can’t possibly remember” how hundreds of moles looked a year earlier.
Ek’s tentative diagnosis of America’s healthcare failure is an incentive-duration mismatch. Employer-linked insurance may retain a member for only two or three years, while preventive investments can require 10–20 years to pay back; the system therefore remains oriented toward acute symptoms. His response is pragmatic rather than sweeping: lower diagnostic costs and create enough outcome data to make long-horizon ROI legible.
The data strategy extends beyond Neko’s own sensors into wearables, research and continuously upgraded diagnostics. Neko already allows Apple Health imports, has completed four clinical trials, has two underway and another four planned, and expects Gen 2 to keep expanding rather than remain a static product for a decade. Ek’s view is that making 10x or 100x more healthcare data available could enable conclusions that today’s relatively small datasets cannot support.
On AI, Ek favors both open and closed models, declines to take a strong position on pacing, and raises compute as an additional risk variable beyond static model classifications. Spotify uses frontier and fine-tuned models because cost, efficiency and control differ by task; meanwhile, a system using 100,000 GPUs may be much more powerful than an open model running on a home PC. His larger complaint is that the industry undercommunicates AI’s “crazy positive stuff,” from personalized music to earlier disease detection.
Deep dive
1. Spotify won by underwriting the incumbent’s downside
The interview starts with Spotify at well over 700 million active users and more than 300 million premium subscribers after the two decades Ek ran it; on January 1, he shifted to executive chairman. Ek started Spotify in 2006 at age 23, before the iPhone and YouTube and while Facebook remained college-only. Amid rampant piracy and lawsuits against individual consumers, his conclusion was blunt: “There’s no way to put the genie back in the bottle.” The product therefore had to feel like “all the world’s music at your fingertips.”
Sweden’s distressed music market created the opening. Fast broadband made piracy effortless, iTunes was unavailable, and Ek recalls the local music industry losing roughly 80% of its revenue—making the country both one of the world’s worst music markets and an unusually receptive laboratory for a legal alternative.
Ek and co-founder Martin committed their prior-startup proceeds to guarantee labels enough revenue to protect the next year’s budget and bonuses. If Spotify failed, executives still got paid; if it worked, they shared the upside. After years of negotiation, Spotify launched in late 2008, expanded to the U.K., then entered the U.S. in 2011.
Stardoll supplied Ek’s operating rehearsal. The site’s average page took roughly four minutes to load; he rearchitected it, hired a new technical team and brought loading below one second, after which traffic “exploded.” He had agreed to help for 6–12 months partly hoping Danny Rimer would fund Spotify—it did not happen—then left to build it anyway.
2. Life after Spotify means building again, not merely investing
Ek had little investable wealth before Spotify’s public listing around 2018, having spent the prior 12–13 years focused almost exclusively on the company. Once he tried investing, the preference became obvious: “I loved building way more than I loved investing.” Advising founders without operating authority proved less satisfying than tackling a problem himself.
Healthcare had occupied him since at least a 2012 or 2013 interview. His starting puzzle was why spending kept rising while outcomes deteriorated. He found no single cause, but focused on chronic disease—including heart health and skin cancer—because early discovery, he says, can make these conditions preventable while keeping treatment cost and suffering low.
Neko co-founder Hjalmar Nilsonne is the company’s brainchild and does most of the work, while Ek remains involved without serving as its day-to-day CEO. Neko’s thesis is that prevention begins with “a lot more data”—deeper within each measurement type, broader across multiple modalities and collected longitudinally. Ek explicitly connects that flywheel to Spotify: more listening data improved the prediction of the next song; richer health histories might similarly improve the prediction of future disease.
3. Neko compresses preventive medicine into one instrumented hour
The $499 Gen 2 visit is vertically integrated across facilities, nurses, doctors, diagnostic equipment and software. Members provide blood for 53 markers, enter a camera rig that captures more than 6,000 high-resolution images, and undergo heart, blood-circulation, grip-strength and other evidence-backed measurements.
Results, including blood work, are available during the same visit for uninterrupted clinician review. The full experience lasts about an hour, though someone with few questions could finish in 30–40 minutes. Ek wants it to become as routine as an annual dentist appointment, while acknowledging that “$500 is still a lot of money.”
The U.S. rollout starts in New York at 300 Lafayette. The discussion also identified Miami and Washington, D.C., as planned locations, with broader U.S. expansion targeted over the coming 12–24 months.
The hosts pressed on whether Neko meaningfully differs from previous integrated-care concepts. Ek emphasized its operating history: eight years of company development, more than 100,000 scans and a recently published third-year data survey—not simply a newly announced thesis packaged around preventive care.
Roughly 1% of members have had a serious undiagnosed medical issue discovered, while many receive guidance around stress, diet, sleep and other lifestyle variables. Most encouraging to Ek, though still early, is that members starting in the worst health condition are improving most; he cited people quitting smoking after seeing and discussing their health status.
4. Longitudinal dermatology shows where AI actually earns its keep
The average person at Neko has about 950 moles, with some having many thousands—far beyond what a normal appointment could inspect consistently. Neko indexes every mole, lesion, rash and area of redness rather than depending on whichever spot a patient or doctor happens to notice.
An AI system flags potential risks, a clinician reviews them, and multiple specialist dermatologists examine anything still concerning. Ek’s model is deliberately hybrid: “It should seamlessly be both AI and amazing clinicians in a great packaged experience,” not an autonomous algorithm substituting for medical judgment.
The larger advantage emerges at the next visit. Because every lesion has been catalogued, the system can detect abnormal change from one year to another; even “the best doctors in the world” cannot reliably remember how 950 separate moles previously looked.
5. Prevention’s obstacle is misaligned payback, not a lack of stated intent
Asked why U.S. hospital visits and drugs can cost multiples of their apparent inputs, Ek declined the invitation to pose as an expert with three sweeping fixes. His narrower diagnosis was “show me the outcome, I’ll show you the incentive”: the system was constructed around a time when infectious disease was the main concern and still rewards intervention after unmistakable symptoms appear.
Employer-linked coverage makes the mismatch worse. A person may remain with an employer—and its insurer—for only two or three years, while prevention might repay its cost over 10, 15 or 20 years. Ek’s proposed wedge is to reduce a speculative million-dollar intervention to, hypothetically, tens of thousands, increasing the chance that someone funds it.
Neko says its $499 price already produces positive unit economics and that some existing clinics are profitable. Yet Ek would not extrapolate those economics into national savings: on what universal annual screening would do to healthcare budgets, “I think it’s too early to say.”
Better measurement could eventually clarify that ROI. Ek finds healthcare datasets surprisingly small by technology-industry standards and argues that making 10x or 100x more data available could yield useful conclusions. Neko has completed four clinical trials, has two underway and another four planned, while publishing aggregate findings annually.
6. Ek wants AI judged by applications, openness and actual compute
On pacing frontier AI, Ek offered no strong view one way or the other. The host—not Ek—had framed the broader debate with examples of crises turning everyone into instant experts; Ek instead emphasized that technologies carry extreme positives and negatives and should be steered toward desired outcomes.
His positive cases are concrete. Spotify could eventually “soundtrack every moment of your life” so music makes users “feel more”; Neko can monitor hundreds of lesions over time. Ek argues the technology industry has done “a terrible disservice” by failing to foreground such broadly beneficial applications.
On model structure, Ek expects the familiar coexistence of open and closed systems. Spotify uses frontier models alongside internally fine-tuned ones because some tasks require lower cost, greater efficiency or tuning unavailable from frontier providers; the host underscored the stakes with output costs of roughly $0.13 versus $30 per million tokens.
Ek’s tentative additional safety variable is compute: a system using 100,000 GPUs may be much more powerful than an open model running on a home PC. The hosts extended that into compute-based access and certification, while Ek kept the idea tentative—“maybe it’s something I’m missing”—rather than presenting it as a finished regulatory scheme.